Design Therapeutics, Inc. (DSGN)
NASDAQ: DSGN · Real-Time Price · USD
3.880
-0.360 (-8.49%)
Apr 25, 2025, 4:00 PM EDT - Market closed
Design Therapeutics Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
54
Market Cap
220.24M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 63.92B |
AbbVie | 57.37B |
AstraZeneca | 54.07B |
Novartis AG | 51.72B |
Eli Lilly and Company | 45.04B |
Thermo Fisher Scientific | 42.90B |
DSGN News
- 6 days ago - Design Therapeutics to Present Phase 1 Data for Fuchs Endothelial Corneal Dystrophy Program at Eyecelerator @ Park City 2025 - GlobeNewsWire
- 11 days ago - Design Therapeutics Appoints Veteran Industry Executive Chris Storgard, M.D., as Chief Medical Officer - GlobeNewsWire
- 7 weeks ago - Design Therapeutics Highlights Progress Across Lead GeneTAC® Programs and Reports Fourth Quarter and Full Year 2024 Financial Results - GlobeNewsWire
- 2 months ago - Design Therapeutics to Participate in Leerink's Global Healthcare Conference - GlobeNewsWire
- 5 months ago - Design Therapeutics to Participate in Multiple Upcoming Investor Conferences - GlobeNewsWire
- 6 months ago - Design Therapeutics Announces Third Quarter 2024 Financial Results and Reviews Near-term Milestones for GeneTACTM Portfolio - GlobeNewsWire
- 9 months ago - Design Therapeutics Announces Second Quarter 2024 Financial Results and Reviews Near-term Milestones for GeneTAC™ Portfolio - GlobeNewsWire
- 1 year ago - Design Therapeutics Announces First Quarter 2024 Financial Results and Highlights Upcoming Program Milestones - GlobeNewsWire